Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Acquiring Nexcelom Bioscience for $260M

NEW YORK – PerkinElmer announced after the close of the market on Wednesday it has reached a deal to acquire Nexcelom Bioscience for $260 million in cash.

The acquisition is expected to close in the second quarter.

Based in Lawrence, Massachusetts, Nexcelom provides tools and instruments for cell counting and analysis, including automated cell counting instruments, image cytometry workstations, assays, cell reagents and other consumables.

The company also provides fit-for-purpose cell counting method selection and development instruments that follow ISO cell counting standards and aid in developing cell, gene, and immune-oncology therapies; virology drugs; and vaccines. The company was founded in 2003 and has about 130 employees in the US, UK, and China, and it expects 2021 revenues of about $40 million, PerkinElmer said.

Nexcelom's capabilities in drug development, combined with PerkinElmer's drug discovery solutions, "will expand our efforts to help academic, government, and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies," PerkinElmer CEO Prahlad Singh said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.